FDA approves use of enzalutamide (Xtandi) for nmCRPC

As we predicted just a couple of weeks ago, on Friday the US Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC), … READ MORE …

“The best” therapy for Gleason 10 prostate cancer

We recently saw (see this link) that men diagnosed with a Gleason score (GS) of 9 or 10 had lower rates of metastasis and better prostate-cancer survival if … READ MORE …

A prostate cancer book that is uniquely useful

There is a large number of books for patients that deal with a diagnosis and management of prostate cancer. However, there is a relatively small number of books that are really valuable for a large number of men (and their partners) who have to deal with a diagnosis of prostate cancer. Very few books on prostate cancer ever make it into a second edition. … READ MORE …

On statins: a race-related update

It is relatively common knowledge — although never actually proven in a large, randomized, placebo-controlled trial — that statins like rosuvastatin (Crestor) and atorvastatin (Lipitor) may be helpful in the management of prostate cancer. … READ MORE …

What’s the “best” form of first-line treatment for mHSPC today?

A new paper in the Annals of Oncology has addressed the critical question regarding what might be “the best” way we currently have to start treatment for a man newly diagnosed with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Testosterone supplements and new AUA guidelines on management of testosterone deficiency

The increasingly widespread use of testosterone supplements has been of concern for many years. In particular, for men with a history of prostate cancer diagnosis, the appropriate use of testosterone supplementation has been a matter of special focus. … READ MORE …

Two leading women talk about the future of treatment of advanced prostate cancer

Nearly 30 years ago, when your sitemaster first attended a prostate cancer meeting (in 1989) related to the upcoming approval of a new drug called flutamide, he doesn’t remember there being a single clinician at the meeting who was female — out of the 150 or so urologists and medical oncologists who had been invited. … READ MORE …